Has David Dao, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,797 in general payments to David Dao, MD across 45 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Dao, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Dao, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Dao, MD

Retina Specialist · Baltimore, MDNPI 1316332455

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 38.5% of the total. Reporting peaked in 2021 at $977 and has fallen 83.9% since, to $157 in 2025. That places this record below the midpoint for retina specialist clinicians in MD, where the typical reported total is $3,416.

$2,797in general payments, 2019–2025

Across 45 payments — averaging $62.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Regeneron Healthcare Solutions, Inc.$1K
AbbVie$723
Alcon$282
Genentech USA, Inc.$231
Mallinckrodt Hospital Products Inc.$144
Bausch & Lomb Americas Inc.$79
plus $262 from 7 others

$300in research payments, 2019–2025

Across 7 payments — averaging $42.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Notal Vision, Inc.$300

What the payments were for

Food & beverage$2,797100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Regeneron Healthcare Solutions, Inc.	12	$1,077
AbbVie(2 entities)	8	$723
Alcon	2	$282
Genentech USA, Inc.	6	$231
Mallinckrodt Hospital Products Inc.	1	$144
Bausch & Lomb Americas Inc.	4	$79
Biogen	4	$72
Harrow Eye, LLC	2	$47
Alimera Sciences, Inc.	2	$47
ANI Pharmaceuticals, Inc.	1	$33
Eyepoint US, Inc.	1	$22
Coherus Oncology, Inc.	1	$22
Sandoz	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,797 in reported general payments places this provider in the 45th percentile of 47 retina specialist providers in Maryland.

See all retina specialist providers in Maryland →

Medicare billing

Part B allowed, 2024

$4,466,984

Medicare patients

1,348

Services billed

76,900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ProlensaBromfenac Sodium	44	$14,892
Prednisolone Acetate	284	$13,752
Bromfenac Sodium	44	$8,609
Ketorolac Tromethamine	361	$7,467
Difluprednate	17	$1,782
Latanoprost	39	$705
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	45	$518
Brimonidine Tartrate	23	$409
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	38	$398
MoxifloxacinMoxifloxacin Hcl	19	$371
Dorzolamide Hcl	18	$308
ErythromycinErythromycin Base	29	$257

Paid to pharmacies, not to this prescriber.

Other retina specialist in Baltimore

Michael ElmanBaltimore$27K
Sidney SchechetBaltimore$23K
Lisa SchocketBaltimore$7K
Heather TamezBaltimore$4K
Sean KimBaltimore$3K
Daniel BrillBaltimore$3K
Christina AntonopoulosBaltimore$304
Kenneth TaubenslagBaltimore$150
Rohit LakhanpalOwings Mills$168K
Brian DoChevy Chase$116K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →